FULL TEST BANK
LEHNE'S PHARMACOTHERAPEUTICS FOR ADVANCED PRACTICE
NURSES AND PHYSICIAN ASSISTANTS 3RD EDITION BY LAURA D.
ROSENTHAL | JACQUELINE ROSENJACK BURCHUM| LATEST VERSION|
ALL CHAPTERS WITH VERIFIED ANSWERS A+
PRINTED PDF| ORIGINAL DIRECTLY FROM THE PUBLISHER| 100% VERIFIED ANSWERS| DOWNLOAD
IMMEDIETLY AFTER THE ORDER
, TABLE OF CONTENTS
UNIT I: INTRODUCTION .......................................................................6
CHAPTER 1: PRESCRIPTIVE AUTHORITY .................................................................................................... 6
CHAPTER 2: RATIONAL DRUG SELECTION AND PRESCRIPTION WRITING ................................................ 9
CHAPTER 3: PROMOTING POSITIVE OUTCOMES OF DRUG THERAPY .................................................... 13
UNIT II: BASIC PRINCIPLES OF PHARMACOLOGY ................................. 17
CHAPTER 4: PHARMACOKINETICS, PHARMACODYNAMICS, AND DRUG INTERACTIONS ....................... 17
CHAPTER 5: ADVERSE DRUG REACTIONS AND MEDICATION ERRORS ................................................... 25
CHAPTER 6: INDIVIDUAL VARIATION IN DRUG RESPONSES ................................................................... 33
CHAPTER 7 GENETIC AND GENOMIC CONSIDERATIONS IN PHARMACOTHERAPEUTICS ....................... 39
UNIT III: DRUG THERAPY ACROSS THE LIFE SPAN ................................ 47
CHAPTER 8: DRUG THERAPY DURING PREGNANCY AND BREAST-FEEDING ........................................... 47
CHAPTER 9: DRUG THERAPY IN PEDIATRIC PATIENTS ............................................................................ 53
CHAPTER 10: DRUG THERAPY IN GERIATRIC PATIENTS .......................................................................... 59
UNIT IV: PERIPHERAL NERVOUS SYSTEM DRUGS ................................ 66
CHAPTER 11: BASIC PRINCIPLES OF NEUROPHARMACOLOGY ............................................................... 66
CHAPTER 12: PHYSIOLOGY OF THE PERIPHERAL NERVOUS SYSTEM ...................................................... 71
CHAPTER 13: MUSCARINIC AGONISTS AND CHOLINESTERASE INHIBITORS........................................... 76
CHAPTER 14 MUSCARINIC ANTAGONISTS .............................................................................................. 81
CHAPTER 15: ADRENERGIC AGONISTS .................................................................................................... 86
CHAPTER 16: ADRENERGIC ANTAGONISTS ............................................................................................. 93
CHAPTER 17: INDIRECT-ACTING ANTIADRENERGIC AGENTS ................................................................ 102
UNIT V: CENTRAL NERVOUS SYSTEM DRUGS .................................... 108
CHAPTER 18: INTRODUCTION TO CENTRAL NERVOUS SYSTEM PHARMACOLOGY .............................. 108
CHAPTER 19: DRUGS FOR PARKINSON'S DISEASE ................................................................................ 113
CHAPTER 20: DRUGS FOR ALZHEIMER'S DISEASE ................................................................................. 119
CHAPTER 21: DRUGS FOR SEIZURE DISORDERS .................................................................................... 125
CHAPTER 22: DRUGS FOR MUSCLE SPASM AND SPASTICITY................................................................ 130
UNIT VI: DRUGS FOR PAIN ............................................................... 136
CHAPTER 23: LOCAL ANESTHETICS ....................................................................................................... 136
, CHAPTER 24: OPIOID ANALGESICS, OPIOID ANTAGONISTS, AND NONOPIOID CENTRALLY ACTING
ANALGESICS .......................................................................................................................................... 142
CHAPTER 25: DRUGS FOR HEADACHE .................................................................................................. 151
UNIT VII: PSYCHOTHERAPEUTIC DRUGS ........................................... 158
CHAPTER 26: ANTIPSYCHOTIC AGENTS AND THEIR USE IN SCHIZOPHRENIA ....................................... 158
CHAPTER 27: ANTIDEPRESSANTS .......................................................................................................... 167
CHAPTER 28: DRUGS FOR BIPOLAR DISORDER ..................................................................................... 173
CHAPTER 29: SEDATIVE-HYPNOTIC DRUGS .......................................................................................... 180
CHAPTER 30: MANAGEMENT OF ANXIETY DISORDERS ........................................................................ 185
CHAPTER 31: CENTRAL NERVOUS SYSTEM STIMULANTS AND ATTENTION-DEFICIT/HYPERACTIVITY
DISORDER .............................................................................................................................................. 191
UNIT VIII: SUBSTANCE USE DISORDERS ............................................ 197
CHAPTER 32: DRUG ABUSE I: BASIC CONSIDERATIONS ........................................................................ 197
CHAPTER 33: DRUG ABUSE II: ALCOHOL ............................................................................................... 202
CHAPTER 34: DRUG ABUSE III: NICOTINE AND SMOKING .................................................................... 209
CHAPTER 35: DRUG ABUSE IV: MAJOR DRUGS OF ABUSE OTHER THAN ALCOHOL AND NICOTINE .... 215
UNIT IX: DRUGS THAT AFFECT THE HEART, BLOOD VESSELS, BLOOD,
AND BLOOD VOLUME ..................................................................... 225
CHAPTER 36: REVIEW OF HEMODYNAMICS ......................................................................................... 225
CHAPTER 37: DIURETICS ....................................................................................................................... 229
CHAPTER 38: DRUGS ACTING ON THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM ........................ 235
CHAPTER 39: CALCIUM CHANNEL BLOCKERS ....................................................................................... 242
CHAPTER 40: VASODILATORS ............................................................................................................... 246
CHAPTER 41: DRUGS FOR HYPERTENSION ........................................................................................... 252
CHAPTER 42: DRUGS FOR HEART FAILURE ........................................................................................... 263
CHAPTER 43: ANTIDYSRHYTHMIC DRUGS ............................................................................................ 274
CHAPTER 44: PROPHYLAXIS OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: DRUGS THAT HELP
NORMALIZE CHOLESTEROL AND TRIGLYCERIDE LEVELS ....................................................................... 286
CHAPTER 45: DRUGS FOR ANGINA PECTORIS....................................................................................... 296
CHAPTER 46: ANTICOAGULANT AND ANTIPLATELET DRUGS ............................................................... 306
CHAPTER 47: DRUGS FOR DEFICIENCY ANEMIAS ................................................................................. 315
UNIT X: DRUGS FOR ENDOCRINE DISORDERS ................................... 324
, CHAPTER 48: DRUGS FOR DIABETES MELLITUS .................................................................................... 324
CHAPTER 49: DRUGS FOR THYROID DISORDERS................................................................................... 332
UNIT XI: REPRODUCTIVE HEALTH..................................................... 340
CHAPTER 50: ESTROGENS AND PROGESTINS: BASIC PHARMACOLOGY AND NONCONTRACEPTIVE
APPLICATIONS ....................................................................................................................................... 340
CHAPTER 51: BIRTH CONTROL .............................................................................................................. 345
CHAPTER 52: ANDROGENS ................................................................................................................... 354
CHAPTER 53: DRUGS FOR BENIGN PROSTATIC HYPERPLASIA .............................................................. 360
CHAPTER 54: DRUGS FOR SEXUAL DYSFUNCTION ................................................................................ 365
CHAPTER 55: DRUGS FOR TRANSGENDER HEALTH .............................................................................. 378
UNIT XII: ANTI-INFLAMMATORY, ANTIALLERGIC, AND IMMUNOLOGIC
DRUGS ........................................................................................... 401
CHAPTER 56: REVIEW OF THE IMMUNE SYSTEM ................................................................................. 401
CHAPTER 57: CHILDHOOD IMMUNIZATION ......................................................................................... 406
CHAPTER 58: ANTIHISTAMINES ............................................................................................................ 414
CHAPTER 59: CYCLOOXYGENASE INHIBITORS: NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND
ACETAMINOPHEN ................................................................................................................................. 421
CHAPTER 60: GLUCOCORTICOIDS IN NONENDOCRINE DISORDERS ..................................................... 429
UNIT XIII: DRUGS FOR BONE AND JOINT DISORDERS ........................ 438
CHAPTER 61: DRUG THERAPY OF RHEUMATOID ARTHRITIS ................................................................ 438
CHAPTER 62: DRUG THERAPY OF GOUT ............................................................................................... 442
CHAPTER 63: DRUGS AFFECTING CALCIUM LEVELS AND BONE MINERALIZATION .............................. 447
UNIT XIV: RESPIRATORY TRACT DRUGS ............................................ 456
CHAPTER 64: DRUGS FOR ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE .................. 456
CHAPTER 65: DRUGS FOR ALLERGIC RHINITIS, COUGH, AND COLDS ................................................... 466
UNIT XV: GASTROINTESTINAL DRUGS .............................................. 474
CHAPTER 66: DRUGS FOR PEPTIC ULCER DISEASE ................................................................................ 474
CHAPTER 67: LAXATIVES ....................................................................................................................... 481
CHAPTER 68: OTHER GASTROINTESTINAL DRUGS ................................................................................ 489
UNIT XVI: NUTRITION AND COMPLIMENTARY THERAPIES ................. 499
CHAPTER 69: VITAMINS ........................................................................................................................ 499
, CHAPTER 70: DRUGS FOR WEIGHT LOSS .............................................................................................. 506
CHAPTER 71: COMPLEMENTARY AND ALTERNATIVE THERAPIES......................................................... 513
UNIT XVII: THERAPY OF INFECTIOUS AND PARASITIC DISEASES ......... 518
CHAPTER 72: BASIC PRINCIPLES OF ANTIMICROBIAL THERAPY ........................................................... 518
CHAPTER 73: DRUGS THAT WEAKEN THE BACTERIAL CELL WALL I: PENICILLINS................................. 524
CHAPTER 74: DRUGS THAT WEAKEN THE BACTERIAL CELL WALL II: OTHER DRUGS ........................... 531
CHAPTER 75: BACTERIOSTATIC INHIBITORS OF PROTEIN SYNTHESIS .................................................. 538
CHAPTER 76: AMINOGLYCOSIDES: BACTERICIDAL INHIBITORS OF PROTEIN SYNTHESIS ..................... 549
CHAPTER 77: SULFONAMIDES AND TRIMETHOPRIM ........................................................................... 558
CHAPTER 78: DRUG THERAPY OF URINARY TRACT INFECTIONS .......................................................... 565
CHAPTER 79: DRUG THERAPY FOR TUBERCULOSIS .............................................................................. 572
CHAPTER 80: MISCELLANEOUS ANTIBACTERIAL DRUGS ...................................................................... 582
CHAPTER 81: ANTIFUNGAL AGENTS ..................................................................................................... 587
CHAPTER 82: ANTIVIRAL AGENTS I: DRUGS FOR NON-HIV VIRAL INFECTIONS .................................... 598
CHAPTER 83: ANTIVIRAL AGENTS II: DRUGS FOR HIV INFECTION ........................................................ 606
CHAPTER 84: DRUG THERAPY OF SEXUALLY TRANSMITTED DISEASES ................................................ 613
CHAPTER 85: ANTHELMINTICS .............................................................................................................. 619
UNIT XVIII: CANCER THERAPY .......................................................... 623
CHAPTER 86 INTRODUCTION TO IMMUNOMODULATORS .................................................................. 623
CHAPTER 87: ANTICANCER DRUGS FOR THE NONSPECIALIST .............................................................. 630
CHAPTER 88: PAIN MANAGEMENT IN PATIENTS WITH CANCER .......................................................... 638
UNIT XIX: DRUGS FOR EYES, EARS, AND SKIN ................................... 647
CHAPTER 89: DRUGS FOR THE EYE ....................................................................................................... 647
CHAPTER 90: DRUGS FOR THE SKIN ...................................................................................................... 654
CHAPTER 91: DRUGS FOR THE EAR ....................................................................................................... 665
UNIT XX: DRUG THERAPY IN ACUTE CARE ........................................ 672
CHAPTER 92: AGENTS AFFECTING THE VOLUME AND ION CONTENT OF BODY FLUIDS ...................... 672
CHAPTER 93: MANAGEMENT OF ST-ELEVATION MYOCARDIAL INFARCTION ...................................... 678
CHAPTER 94: DRUGS FOR ACUTE CARE ................................................................................................ 685
,Unit i: introduction
Chapter 1: prescriptive authority
Multiple choice
1. An aprn works in a urology clinic under the supervision of a physician who does not restrict the
types of medications the aprn is allowed to prescribe. State law does not require the aprn to practice
under physician supervision. How would the aprn’s prescriptive authority be described?
A. Full authority
B. Independent
C. Without limitation
D. Limited authority
Answer>>b
The aprn has independent prescriptive authority because the regulating body does not require that the
aprn work under physician supervision. Full prescriptive authority gives the provider the right to
prescribe independently and without limitation. Limited authority places restrictions on the types of
drugs that can be prescribed.dif: cognitive level: comprehensionref: p. 1top: nursing process: i msc:
nclex client needs category: physiologic integrity: pharmacologic and parenteral therapies
2. Which factors increase the need for aprns to have full prescriptive authority?
A. More patients will have access to health care.
B. Enrollment in medical schools is predicted to decrease.
C. Physician’s assistants are being utilized less often.
D. Aprn education is more complex than education for physicians.
Answer>>a
, Implementation of the affordable care act has increased the number of individuals with health care
coverage, and thus the number who have access to health care services. The increase in the number of
patients creates the need for more providers with prescriptive authority. Aprns can fill this practice
gap.dif: cognitive level: comprehensionref: p. 2top: nursing process: implementation msc: nclex client
needs category: physiologic integrity: pharmacologic and parenteral therapies
3. Which factors could be attributed to limited prescriptive authority for aprns? Select all that
apply.
A. Inaccessibility of patient care
B. Higher health care costs
C. Higher quality medical treatment
D. Improved collaborative care
E. Enhanced health literacy
Answer>>a , b
Limiting prescriptive authority for aprns can create barriers to quality, affordable, and accessible patient
care. It may also lead to poor collaboration among providers and higher health care costs. It would not
directly impact patient’s health literacy.dif: cognitive level: comprehensionref:
P. 2top: nursing process: implementation msc: nclex client needs category: physiologic integrity:
pharmacologic and parenteral therapies
4. Which aspects support the aprn’s provision for full prescriptive authority? Select all that apply.
A. Clinical education includes prescription of medications and disease processes.
B. Federal regulations support the provision of full authority for aprns.
C. National examinations provide validation of the aprn’s ability to provide safecare.
D. Licensure ensures compliance with health care and safety standards.
LEHNE'S PHARMACOTHERAPEUTICS FOR ADVANCED PRACTICE
NURSES AND PHYSICIAN ASSISTANTS 3RD EDITION BY LAURA D.
ROSENTHAL | JACQUELINE ROSENJACK BURCHUM| LATEST VERSION|
ALL CHAPTERS WITH VERIFIED ANSWERS A+
PRINTED PDF| ORIGINAL DIRECTLY FROM THE PUBLISHER| 100% VERIFIED ANSWERS| DOWNLOAD
IMMEDIETLY AFTER THE ORDER
, TABLE OF CONTENTS
UNIT I: INTRODUCTION .......................................................................6
CHAPTER 1: PRESCRIPTIVE AUTHORITY .................................................................................................... 6
CHAPTER 2: RATIONAL DRUG SELECTION AND PRESCRIPTION WRITING ................................................ 9
CHAPTER 3: PROMOTING POSITIVE OUTCOMES OF DRUG THERAPY .................................................... 13
UNIT II: BASIC PRINCIPLES OF PHARMACOLOGY ................................. 17
CHAPTER 4: PHARMACOKINETICS, PHARMACODYNAMICS, AND DRUG INTERACTIONS ....................... 17
CHAPTER 5: ADVERSE DRUG REACTIONS AND MEDICATION ERRORS ................................................... 25
CHAPTER 6: INDIVIDUAL VARIATION IN DRUG RESPONSES ................................................................... 33
CHAPTER 7 GENETIC AND GENOMIC CONSIDERATIONS IN PHARMACOTHERAPEUTICS ....................... 39
UNIT III: DRUG THERAPY ACROSS THE LIFE SPAN ................................ 47
CHAPTER 8: DRUG THERAPY DURING PREGNANCY AND BREAST-FEEDING ........................................... 47
CHAPTER 9: DRUG THERAPY IN PEDIATRIC PATIENTS ............................................................................ 53
CHAPTER 10: DRUG THERAPY IN GERIATRIC PATIENTS .......................................................................... 59
UNIT IV: PERIPHERAL NERVOUS SYSTEM DRUGS ................................ 66
CHAPTER 11: BASIC PRINCIPLES OF NEUROPHARMACOLOGY ............................................................... 66
CHAPTER 12: PHYSIOLOGY OF THE PERIPHERAL NERVOUS SYSTEM ...................................................... 71
CHAPTER 13: MUSCARINIC AGONISTS AND CHOLINESTERASE INHIBITORS........................................... 76
CHAPTER 14 MUSCARINIC ANTAGONISTS .............................................................................................. 81
CHAPTER 15: ADRENERGIC AGONISTS .................................................................................................... 86
CHAPTER 16: ADRENERGIC ANTAGONISTS ............................................................................................. 93
CHAPTER 17: INDIRECT-ACTING ANTIADRENERGIC AGENTS ................................................................ 102
UNIT V: CENTRAL NERVOUS SYSTEM DRUGS .................................... 108
CHAPTER 18: INTRODUCTION TO CENTRAL NERVOUS SYSTEM PHARMACOLOGY .............................. 108
CHAPTER 19: DRUGS FOR PARKINSON'S DISEASE ................................................................................ 113
CHAPTER 20: DRUGS FOR ALZHEIMER'S DISEASE ................................................................................. 119
CHAPTER 21: DRUGS FOR SEIZURE DISORDERS .................................................................................... 125
CHAPTER 22: DRUGS FOR MUSCLE SPASM AND SPASTICITY................................................................ 130
UNIT VI: DRUGS FOR PAIN ............................................................... 136
CHAPTER 23: LOCAL ANESTHETICS ....................................................................................................... 136
, CHAPTER 24: OPIOID ANALGESICS, OPIOID ANTAGONISTS, AND NONOPIOID CENTRALLY ACTING
ANALGESICS .......................................................................................................................................... 142
CHAPTER 25: DRUGS FOR HEADACHE .................................................................................................. 151
UNIT VII: PSYCHOTHERAPEUTIC DRUGS ........................................... 158
CHAPTER 26: ANTIPSYCHOTIC AGENTS AND THEIR USE IN SCHIZOPHRENIA ....................................... 158
CHAPTER 27: ANTIDEPRESSANTS .......................................................................................................... 167
CHAPTER 28: DRUGS FOR BIPOLAR DISORDER ..................................................................................... 173
CHAPTER 29: SEDATIVE-HYPNOTIC DRUGS .......................................................................................... 180
CHAPTER 30: MANAGEMENT OF ANXIETY DISORDERS ........................................................................ 185
CHAPTER 31: CENTRAL NERVOUS SYSTEM STIMULANTS AND ATTENTION-DEFICIT/HYPERACTIVITY
DISORDER .............................................................................................................................................. 191
UNIT VIII: SUBSTANCE USE DISORDERS ............................................ 197
CHAPTER 32: DRUG ABUSE I: BASIC CONSIDERATIONS ........................................................................ 197
CHAPTER 33: DRUG ABUSE II: ALCOHOL ............................................................................................... 202
CHAPTER 34: DRUG ABUSE III: NICOTINE AND SMOKING .................................................................... 209
CHAPTER 35: DRUG ABUSE IV: MAJOR DRUGS OF ABUSE OTHER THAN ALCOHOL AND NICOTINE .... 215
UNIT IX: DRUGS THAT AFFECT THE HEART, BLOOD VESSELS, BLOOD,
AND BLOOD VOLUME ..................................................................... 225
CHAPTER 36: REVIEW OF HEMODYNAMICS ......................................................................................... 225
CHAPTER 37: DIURETICS ....................................................................................................................... 229
CHAPTER 38: DRUGS ACTING ON THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM ........................ 235
CHAPTER 39: CALCIUM CHANNEL BLOCKERS ....................................................................................... 242
CHAPTER 40: VASODILATORS ............................................................................................................... 246
CHAPTER 41: DRUGS FOR HYPERTENSION ........................................................................................... 252
CHAPTER 42: DRUGS FOR HEART FAILURE ........................................................................................... 263
CHAPTER 43: ANTIDYSRHYTHMIC DRUGS ............................................................................................ 274
CHAPTER 44: PROPHYLAXIS OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: DRUGS THAT HELP
NORMALIZE CHOLESTEROL AND TRIGLYCERIDE LEVELS ....................................................................... 286
CHAPTER 45: DRUGS FOR ANGINA PECTORIS....................................................................................... 296
CHAPTER 46: ANTICOAGULANT AND ANTIPLATELET DRUGS ............................................................... 306
CHAPTER 47: DRUGS FOR DEFICIENCY ANEMIAS ................................................................................. 315
UNIT X: DRUGS FOR ENDOCRINE DISORDERS ................................... 324
, CHAPTER 48: DRUGS FOR DIABETES MELLITUS .................................................................................... 324
CHAPTER 49: DRUGS FOR THYROID DISORDERS................................................................................... 332
UNIT XI: REPRODUCTIVE HEALTH..................................................... 340
CHAPTER 50: ESTROGENS AND PROGESTINS: BASIC PHARMACOLOGY AND NONCONTRACEPTIVE
APPLICATIONS ....................................................................................................................................... 340
CHAPTER 51: BIRTH CONTROL .............................................................................................................. 345
CHAPTER 52: ANDROGENS ................................................................................................................... 354
CHAPTER 53: DRUGS FOR BENIGN PROSTATIC HYPERPLASIA .............................................................. 360
CHAPTER 54: DRUGS FOR SEXUAL DYSFUNCTION ................................................................................ 365
CHAPTER 55: DRUGS FOR TRANSGENDER HEALTH .............................................................................. 378
UNIT XII: ANTI-INFLAMMATORY, ANTIALLERGIC, AND IMMUNOLOGIC
DRUGS ........................................................................................... 401
CHAPTER 56: REVIEW OF THE IMMUNE SYSTEM ................................................................................. 401
CHAPTER 57: CHILDHOOD IMMUNIZATION ......................................................................................... 406
CHAPTER 58: ANTIHISTAMINES ............................................................................................................ 414
CHAPTER 59: CYCLOOXYGENASE INHIBITORS: NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND
ACETAMINOPHEN ................................................................................................................................. 421
CHAPTER 60: GLUCOCORTICOIDS IN NONENDOCRINE DISORDERS ..................................................... 429
UNIT XIII: DRUGS FOR BONE AND JOINT DISORDERS ........................ 438
CHAPTER 61: DRUG THERAPY OF RHEUMATOID ARTHRITIS ................................................................ 438
CHAPTER 62: DRUG THERAPY OF GOUT ............................................................................................... 442
CHAPTER 63: DRUGS AFFECTING CALCIUM LEVELS AND BONE MINERALIZATION .............................. 447
UNIT XIV: RESPIRATORY TRACT DRUGS ............................................ 456
CHAPTER 64: DRUGS FOR ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE .................. 456
CHAPTER 65: DRUGS FOR ALLERGIC RHINITIS, COUGH, AND COLDS ................................................... 466
UNIT XV: GASTROINTESTINAL DRUGS .............................................. 474
CHAPTER 66: DRUGS FOR PEPTIC ULCER DISEASE ................................................................................ 474
CHAPTER 67: LAXATIVES ....................................................................................................................... 481
CHAPTER 68: OTHER GASTROINTESTINAL DRUGS ................................................................................ 489
UNIT XVI: NUTRITION AND COMPLIMENTARY THERAPIES ................. 499
CHAPTER 69: VITAMINS ........................................................................................................................ 499
, CHAPTER 70: DRUGS FOR WEIGHT LOSS .............................................................................................. 506
CHAPTER 71: COMPLEMENTARY AND ALTERNATIVE THERAPIES......................................................... 513
UNIT XVII: THERAPY OF INFECTIOUS AND PARASITIC DISEASES ......... 518
CHAPTER 72: BASIC PRINCIPLES OF ANTIMICROBIAL THERAPY ........................................................... 518
CHAPTER 73: DRUGS THAT WEAKEN THE BACTERIAL CELL WALL I: PENICILLINS................................. 524
CHAPTER 74: DRUGS THAT WEAKEN THE BACTERIAL CELL WALL II: OTHER DRUGS ........................... 531
CHAPTER 75: BACTERIOSTATIC INHIBITORS OF PROTEIN SYNTHESIS .................................................. 538
CHAPTER 76: AMINOGLYCOSIDES: BACTERICIDAL INHIBITORS OF PROTEIN SYNTHESIS ..................... 549
CHAPTER 77: SULFONAMIDES AND TRIMETHOPRIM ........................................................................... 558
CHAPTER 78: DRUG THERAPY OF URINARY TRACT INFECTIONS .......................................................... 565
CHAPTER 79: DRUG THERAPY FOR TUBERCULOSIS .............................................................................. 572
CHAPTER 80: MISCELLANEOUS ANTIBACTERIAL DRUGS ...................................................................... 582
CHAPTER 81: ANTIFUNGAL AGENTS ..................................................................................................... 587
CHAPTER 82: ANTIVIRAL AGENTS I: DRUGS FOR NON-HIV VIRAL INFECTIONS .................................... 598
CHAPTER 83: ANTIVIRAL AGENTS II: DRUGS FOR HIV INFECTION ........................................................ 606
CHAPTER 84: DRUG THERAPY OF SEXUALLY TRANSMITTED DISEASES ................................................ 613
CHAPTER 85: ANTHELMINTICS .............................................................................................................. 619
UNIT XVIII: CANCER THERAPY .......................................................... 623
CHAPTER 86 INTRODUCTION TO IMMUNOMODULATORS .................................................................. 623
CHAPTER 87: ANTICANCER DRUGS FOR THE NONSPECIALIST .............................................................. 630
CHAPTER 88: PAIN MANAGEMENT IN PATIENTS WITH CANCER .......................................................... 638
UNIT XIX: DRUGS FOR EYES, EARS, AND SKIN ................................... 647
CHAPTER 89: DRUGS FOR THE EYE ....................................................................................................... 647
CHAPTER 90: DRUGS FOR THE SKIN ...................................................................................................... 654
CHAPTER 91: DRUGS FOR THE EAR ....................................................................................................... 665
UNIT XX: DRUG THERAPY IN ACUTE CARE ........................................ 672
CHAPTER 92: AGENTS AFFECTING THE VOLUME AND ION CONTENT OF BODY FLUIDS ...................... 672
CHAPTER 93: MANAGEMENT OF ST-ELEVATION MYOCARDIAL INFARCTION ...................................... 678
CHAPTER 94: DRUGS FOR ACUTE CARE ................................................................................................ 685
,Unit i: introduction
Chapter 1: prescriptive authority
Multiple choice
1. An aprn works in a urology clinic under the supervision of a physician who does not restrict the
types of medications the aprn is allowed to prescribe. State law does not require the aprn to practice
under physician supervision. How would the aprn’s prescriptive authority be described?
A. Full authority
B. Independent
C. Without limitation
D. Limited authority
Answer>>b
The aprn has independent prescriptive authority because the regulating body does not require that the
aprn work under physician supervision. Full prescriptive authority gives the provider the right to
prescribe independently and without limitation. Limited authority places restrictions on the types of
drugs that can be prescribed.dif: cognitive level: comprehensionref: p. 1top: nursing process: i msc:
nclex client needs category: physiologic integrity: pharmacologic and parenteral therapies
2. Which factors increase the need for aprns to have full prescriptive authority?
A. More patients will have access to health care.
B. Enrollment in medical schools is predicted to decrease.
C. Physician’s assistants are being utilized less often.
D. Aprn education is more complex than education for physicians.
Answer>>a
, Implementation of the affordable care act has increased the number of individuals with health care
coverage, and thus the number who have access to health care services. The increase in the number of
patients creates the need for more providers with prescriptive authority. Aprns can fill this practice
gap.dif: cognitive level: comprehensionref: p. 2top: nursing process: implementation msc: nclex client
needs category: physiologic integrity: pharmacologic and parenteral therapies
3. Which factors could be attributed to limited prescriptive authority for aprns? Select all that
apply.
A. Inaccessibility of patient care
B. Higher health care costs
C. Higher quality medical treatment
D. Improved collaborative care
E. Enhanced health literacy
Answer>>a , b
Limiting prescriptive authority for aprns can create barriers to quality, affordable, and accessible patient
care. It may also lead to poor collaboration among providers and higher health care costs. It would not
directly impact patient’s health literacy.dif: cognitive level: comprehensionref:
P. 2top: nursing process: implementation msc: nclex client needs category: physiologic integrity:
pharmacologic and parenteral therapies
4. Which aspects support the aprn’s provision for full prescriptive authority? Select all that apply.
A. Clinical education includes prescription of medications and disease processes.
B. Federal regulations support the provision of full authority for aprns.
C. National examinations provide validation of the aprn’s ability to provide safecare.
D. Licensure ensures compliance with health care and safety standards.
